Hinova Pharmaceuticals Inc. A Asset Resilience Ratio

Latest as of June 2025: 15.84%

Hinova Pharmaceuticals Inc. A asset resilience ratio. Hinova Pharmaceuticals Inc. A (688302) has an Asset Resilience Ratio of 15.84% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Hinova Pharmaceuticals Inc. A to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥220.52 Million

≈ $32.27 Million USD Cash + Short-term Investments

Total Assets

CN¥1.39 Billion

≈ $203.78 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio of Hinova Pharmaceuticals Inc. A (2019–2024)

Asset resilience ratio of Hinova Pharmaceuticals Inc. A from 2019 to 2024. This chart shows how Hinova Pharmaceuticals Inc. A's Asset Resilience Ratio has changed over time. Read Hinova Pharmaceuticals Inc. A (688302) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Hinova Pharmaceuticals Inc. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 688302 current and non-current assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥220.52 Million	15.84%
Total Liquid Assets	CN¥220.52 Million	15.84%

Asset Resilience Insights

Good Liquidity Position: Hinova Pharmaceuticals Inc. A maintains a healthy 15.84% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Hinova Pharmaceuticals Inc. A Industry Peers by Asset Resilience Ratio

Compare Hinova Pharmaceuticals Inc. A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	36.07%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
3SBio Inc F:83B	Biotechnology	10.64%

Hinova Pharmaceuticals Inc. A Asset Resilience Ratio by Year (2019–2024)

Hinova Pharmaceuticals Inc. A asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Hinova Pharmaceuticals Inc. A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	15.46%	CN¥210.49 Million ≈ $30.80 Million	CN¥1.36 Billion ≈ $199.24 Million	-4.03pp
2023-12-31	19.48%	CN¥290.62 Million ≈ $42.53 Million	CN¥1.49 Billion ≈ $218.26 Million	-1.62pp
2022-12-31	21.11%	CN¥366.24 Million ≈ $53.59 Million	CN¥1.74 Billion ≈ $253.90 Million	+13.28pp
2019-12-31	7.83%	CN¥3.50 Million ≈ $512.16K	CN¥44.72 Million ≈ $6.54 Million	--

pp = percentage points

About Hinova Pharmaceuticals Inc. A

SHG:688302 China Biotechnology

Market Cap

$486.69 Million

CN¥3.33 Billion CNY

Market Cap Rank

#12027 Global

#3470 in China

Share Price

CN¥33.59

Change (1 day)

-5.35%

52-Week Range

CN¥27.68 - CN¥57.00

All Time High

CN¥74.97